Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 6/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.34 |
| ▸ | MLYCD | O95822 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.33 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | VNN1 | O95497 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4655981 | 0.84 | RXRA (0.38) | RXRAGRIN1GRIN2BABL1HRH3 | |
| SCHEMBL14411905 | 0.82 | RXRA (0.37) | RXRAGRIN1GRIN2BPRMT6DHODH | |
| SCHEMBL4655950 | 0.79 | LMNA (0.39) | RXRAGRIN1GRIN2BABL1PRMT6 | |
| SCHEMBL4655050 | 0.70 | RXRA (0.31) | RXRAGRIN1GRIN2B | |
| SCHEMBL14006357 | 0.68 | PRMT6 (0.47) | RXRAGRIN1GRIN2BPRMT6 | |
| SCHEMBL9062115 | 0.68 | RXRA (0.48) | RXRAGRIN1GRIN2BPRMT6 | |
| SCHEMBL4575060 | 0.68 | BCHE (0.43) | RXRAGRIN1GRIN2BPRMT6NR1H2 | |
| SCHEMBL9062321 | 0.67 | RXRA (0.47) | RXRAGRIN1GRIN2BPRMT6 | |
| SCHEMBL5537171 | 0.66 | SLC6A4 (0.41) | ABL1L3MBTL1HCRTR2SERPINE1 | |
| SCHEMBL4655009 | 0.66 | LMNA (0.38) | RXRAGRIN1GRIN2BPRMT6VNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996198-A1 | ALKYLAMINE-SUBSTITUTED BICYCLIC ARYL COMPOUNDS USEFUL AS MODULATORS OF PPAR | Kalypsys, Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007109577-A1 | ALKYLAMINE-SUBSTITUTED BICYCLIC ARYL COMPOUNDS USEFUL AS MODULATORS OF PPAR | KALYPSYS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070219193-A1 | ALKYLAMINE-SUBSTITUTED BICYCLIC ARYL COMPOUNDS USEFUL AS MODULATORS OF PPAR | KALYPSYS, INC (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219193-A1 | ALKYLAMINE-SUBSTITUTED BICYCLIC ARYL COMPOUNDS USEFUL AS MODULATORS OF PPAR | KALYPSYS, INC (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219193-A1 | ALKYLAMINE-SUBSTITUTED BICYCLIC ARYL COMPOUNDS USEFUL AS MODULATORS OF PPAR | KALYPSYS, INC (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219193-A1 | ALKYLAMINE-SUBSTITUTED BICYCLIC ARYL COMPOUNDS USEFUL AS MODULATORS OF PPAR | PPARG, PPARA, PPARD | RXRA 20/4885GRIN1 1336/4885GRIN2B 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.